Data from Weizmann Institute of Science Provide New Insights into Personalized Medicine (Single Cell Analysis of Pre-Treatment Peripheral Immune Composition Can Predict CAR-T Outcomes in Patients with Diffuse Large B-Cell Lymphoma).

The research from the Weizmann Institute of Science in Israel focuses on using single-cell analysis to predict outcomes of CAR-T cell therapy in patients with Diffuse Large B-Cell Lymphoma. By analyzing peripheral blood samples, researchers identified specific cellular and molecular features associated with treatment response. The study found that patients with high B-cells in their blood at the time of leukapheresis achieved complete remission, while non-responders showed enrichment of specific myeloid cell populations. The findings suggest potential biomarkers for predicting treatment response and improving personalized therapy for high-risk patients. [Extracted from the article]